Biotech Values

[biotech_researcher]

FDA tentatively approves Mylan's generic Eliquis

• The FDA has tentatively approved Mylan N.V.'s (MYL -3.3%) generic version of Bristol-Myers Squibb's (BMY -0.1%) blood thinner Eliquis (apixaban).
• Tentative approval means that MYL's marketing application met the requirements for approval, but patent issues need to be resolved before full approval is granted.